Cipla declared partnership with Wellthy Therapeutics to offer a combination of pharmacotherapy and digital therapeutics for improved patient outcomes in the chronic therapies of diabetology and cardiology.
Cipla wholly-owned subsidiary Goldencross Pharma has inked an agreement to acquire the minority stake in the Mumbai-based firm for a cash consideration of Rs 10.5 crore, Cipla said in a regulatory filing.
This coordinated effort will unite conduct science, certifiable clinical proof and AI to give constant checking, instructing and exhortation to patients, and virtual clinical help to specialists.
“The future of health care will be driven by increased use of technology, and this partnership gives Cipla the ability to offer this combination of prescription drugs and artificial intelligence-powered digital therapeutics to patients in cardio-metabolic health,” Cipla Managing Director & Global Chief Executive Officer Umang Vohra said in a statement.
This partnership is a result of Cipla’s campaign, Innoventia, which was envisioned as a first-of-its-kind challenge by an Indian pharmaceutical company to encourage innovation-led entrepreneurship and to harness disruptive ideas in healthcare to fulfil unmet patient needs.
Umang Vohra, MD & Global CEO of Cipla, said, “The future of healthcare will be driven by increased use of technology, and this partnership gives Cipla the ability to offer this combination of prescription drugs and artificial intelligence-powered digital therapeutics to patients in cardio-metabolic health. It will allow patients to make informed decisions and take charge of their own health. By pairing our pharmacotherapy strengths with the digital approach to healthcare of Wellthy Therapeutics, we will add to its diversified portfolio in the cardio-metabolic area to provide holistic care to patients from awareness, diagnosis and compliance to wellbeing.”
Abhishek Shah, Co-founder & CEO of Wellthy Therapeutics, said, “We are excited to work with Cipla to bring digital therapeutics to patients in India. Companion digital therapeutics are redefining the treatment of chronic conditions, by helping personalize and simplify disease management for patients and driving precision clinical insights to clinicians. With the combination of Cipla’s world-class formulations and clinically-validated digital therapeutics of Wellthy Therapeutics, we look forward to helping empower and inspire millions of patients to achieve better sustainable health outcomes.”
About Wellthy Therapeutics Private Limited
It develops an AI-based mobile application to help patients suffering from type-2 diabetes. The programme in the application offers patients real-time instructions from health coaches, personalized self-management education, and an AI-powered bot that will answer queries.
Cipla Limited was founded in 1935 and is based in Mumbai, India. It offers active pharmaceutical ingredients; and formulations in various therapeutic areas, such as women’s health, cardiovascular, children’s health, dermatology and cosmeceuticals, diabetes, HIV-AIDS, hepatitis, oncology, infectious diseases and critical care, malaria, neurosciences, ophthalmology, osteoporosis, respiratory, and urology. It exports its products to Africa, the Middle East, Latin America, Asia, North America, Australia, New Zealand, Russia, and internationally.